BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 27748760)

  • 1. Glutamine activates STAT3 to control cancer cell proliferation independently of glutamine metabolism.
    Cacace A; Sboarina M; Vazeille T; Sonveaux P
    Oncogene; 2017 Apr; 36(15):2074-2084. PubMed ID: 27748760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lactate promotes glutamine uptake and metabolism in oxidative cancer cells.
    Pérez-Escuredo J; Dadhich RK; Dhup S; Cacace A; Van Hée VF; De Saedeleer CJ; Sboarina M; Rodriguez F; Fontenille MJ; Brisson L; Porporato PE; Sonveaux P
    Cell Cycle; 2016; 15(1):72-83. PubMed ID: 26636483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutamine affects T24 bladder cancer cell proliferation by activating STAT3 through ROS and glutaminolysis.
    Sun N; Liang Y; Chen Y; Wang L; Li D; Liang Z; Sun L; Wang Y; Niu H
    Int J Mol Med; 2019 Dec; 44(6):2189-2200. PubMed ID: 31661119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC.
    Liu W; Le A; Hancock C; Lane AN; Dang CV; Fan TW; Phang JM
    Proc Natl Acad Sci U S A; 2012 Jun; 109(23):8983-8. PubMed ID: 22615405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer.
    Grinde MT; Hilmarsdottir B; Tunset HM; Henriksen IM; Kim J; Haugen MH; Rye MB; Mælandsmo GM; Moestue SA
    Breast Cancer Res; 2019 May; 21(1):61. PubMed ID: 31088535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-talk between ER and HER2 regulates c-MYC-mediated glutamine metabolism in aromatase inhibitor resistant breast cancer cells.
    Chen Z; Wang Y; Warden C; Chen S
    J Steroid Biochem Mol Biol; 2015 May; 149():118-27. PubMed ID: 25683269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway.
    Balanis N; Wendt MK; Schiemann BJ; Wang Z; Schiemann WP; Carlin CR
    J Biol Chem; 2013 Jun; 288(25):17954-67. PubMed ID: 23653350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. STAT3 and HIF1α cooperatively activate HIF1 target genes in MDA-MB-231 and RCC4 cells.
    Pawlus MR; Wang L; Hu CJ
    Oncogene; 2014 Mar; 33(13):1670-9. PubMed ID: 23604114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stat3 and CCAAT/enhancer binding protein beta (C/EBP-beta) regulate Jab1/CSN5 expression in mammary carcinoma cells.
    Shackleford TJ; Zhang Q; Tian L; Vu TT; Korapati AL; Baumgartner AM; Le XF; Liao WS; Claret FX
    Breast Cancer Res; 2011 Jun; 13(3):R65. PubMed ID: 21689417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dlx-2 and glutaminase upregulate epithelial-mesenchymal transition and glycolytic switch.
    Lee SY; Jeon HM; Ju MK; Jeong EK; Kim CH; Park HG; Han SI; Kang HS
    Oncotarget; 2016 Feb; 7(7):7925-39. PubMed ID: 26771232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous siRNA targeting of Src and downstream signaling molecules inhibit tumor formation and metastasis of a human model breast cancer cell line.
    Bjorge JD; Pang AS; Funnell M; Chen KY; Diaz R; Magliocco AM; Fujita DJ
    PLoS One; 2011 Apr; 6(4):e19309. PubMed ID: 21541295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development.
    Rivas MA; Venturutti L; Huang YW; Schillaci R; Huang TH; Elizalde PV
    Breast Cancer Res; 2012 May; 14(3):R77. PubMed ID: 22583478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYC-induced cancer cell energy metabolism and therapeutic opportunities.
    Dang CV; Le A; Gao P
    Clin Cancer Res; 2009 Nov; 15(21):6479-83. PubMed ID: 19861459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells.
    Shin DS; Kim HN; Shin KD; Yoon YJ; Kim SJ; Han DC; Kwon BM
    Cancer Res; 2009 Jan; 69(1):193-202. PubMed ID: 19118003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyr23 phosphorylation of Anxa2 enhances STAT3 activation and promotes proliferation and invasion of breast cancer cells.
    Yuan J; Yang Y; Gao Z; Wang Z; Ji W; Song W; Zhang F; Niu R
    Breast Cancer Res Treat; 2017 Jul; 164(2):327-340. PubMed ID: 28470457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Withaferin A inhibits activation of signal transducer and activator of transcription 3 in human breast cancer cells.
    Lee J; Hahm ER; Singh SV
    Carcinogenesis; 2010 Nov; 31(11):1991-8. PubMed ID: 20724373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction.
    Wise DR; DeBerardinis RJ; Mancuso A; Sayed N; Zhang XY; Pfeiffer HK; Nissim I; Daikhin E; Yudkoff M; McMahon SB; Thompson CB
    Proc Natl Acad Sci U S A; 2008 Dec; 105(48):18782-7. PubMed ID: 19033189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MYC regulates the unfolded protein response and glucose and glutamine uptake in endocrine resistant breast cancer.
    Shajahan-Haq AN; Cook KL; Schwartz-Roberts JL; Eltayeb AE; Demas DM; Warri AM; Facey CO; Hilakivi-Clarke LA; Clarke R
    Mol Cancer; 2014 Oct; 13():239. PubMed ID: 25339305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PKM2 promotes glucose metabolism through a let-7a-5p/Stat3/hnRNP-A1 regulatory feedback loop in breast cancer cells.
    Yao A; Xiang Y; Si YR; Fan LJ; Li JP; Li H; Guo W; He HX; Liang XJ; Tan Y; Bao LY; Liao XH
    J Cell Biochem; 2019 Apr; 120(4):6542-6554. PubMed ID: 30368881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding of galectin-1 to integrin β1 potentiates drug resistance by promoting survivin expression in breast cancer cells.
    Nam K; Son SH; Oh S; Jeon D; Kim H; Noh DY; Kim S; Shin I
    Oncotarget; 2017 May; 8(22):35804-35823. PubMed ID: 28415760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.